Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a research note issued on Thursday.

Several other brokerages have also recently issued reports on SAN. Societe Generale set a €100.00 ($114.94) price target on Sanofi SA and gave the company a “buy” rating in a research note on Thursday, March 23rd. Jefferies Group LLC set a €92.00 ($105.75) price target on Sanofi SA and gave the company a “neutral” rating in a research note on Monday, May 29th. Berenberg Bank set a €97.00 ($111.49) price target on Sanofi SA and gave the company a “neutral” rating in a research note on Thursday, May 11th. Deutsche Bank AG set a €96.00 ($110.34) price target on Sanofi SA and gave the company a “buy” rating in a research note on Friday, March 24th. Finally, Morgan Stanley set a €91.00 ($104.60) price target on Sanofi SA and gave the company a “buy” rating in a research note on Tuesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company. Sanofi SA has an average rating of “Hold” and a consensus target price of €88.19 ($101.36).

Sanofi SA (EPA:SAN) opened at 81.52 on Thursday. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The stock has a 50 day moving average price of €25.48 and a 200-day moving average price of €25.74. The firm has a market capitalization of €102.94 billion and a PE ratio of 11.28.

TRADEMARK VIOLATION NOTICE: “Sanofi SA (SAN) Stock Rating Reaffirmed by J P Morgan Chase & Co” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/07/22/sanofi-sa-san-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.